Stimguard LLC will begin enrollment for a head-to-head study of its Chronic Affarent Nerve Stimulator (CAN-stim) against Medtronic plc's gold standard Interstim device in treatment of urgency urinary incontinence from over active bladder (OAB) not controlled by medication, following FDA approval of the trial with an investigational device exemption (IDE). Privately held Stimguard's device can be implanted in a physician's office with ultrasound guidance, avoiding a surgical procedure and general anesthesia required for the sacral device.